Pasireotide + Diazoxide
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gastro-enteropancreatic Neuroendocrine Tumor
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Trial Timeline
Apr 1, 2016 → Jun 1, 2016
NCT ID
NCT02779257About Pasireotide + Diazoxide
Pasireotide + Diazoxide is a approved stage product being developed by Novartis for Gastro-enteropancreatic Neuroendocrine Tumor. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02779257. Target conditions include Gastro-enteropancreatic Neuroendocrine Tumor.
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02779257 | Approved | Withdrawn |
Competing Products
1 competing product in Gastro-enteropancreatic Neuroendocrine Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satoreotide trizoxetan 5-20μg + Satoreotide trizoxetan 30-45μg | Ipsen | Phase 2 | 32 |